| Literature DB >> 34115439 |
Michelle Lubetzky1, Ekamol Tantisattamo2, Miklos Z Molnar3, Krista L Lentine4, Arpita Basu5, Ronald Parsons5, Kenneth J Woodside6, Martha Pavlakis7, Christopher Blosser8, Neeraj Singh9, Beatrice P Concepcion10, Deborah Adey11, Garauv Gupta12, Arman Faravardeh13, Edward Kraus14, Song Ong15, Leonardo Riella16, John Friedewald17, Alex Wiseman18, Amtul Aala7, Darshana M Dadhania1, Tarek Alhamad19.
Abstract
The return to dialysis after allograft failure is associated with increased morbidity and mortality. This transition is made more complex by the rising numbers of patients who seek repeat transplantation and therefore may have indications for remaining on low levels of immunosuppression, despite the potential increased morbidity. Management strategies vary across providers, driven by limited data on how to transition off immunosuppression as the allograft fails and a paucity of randomized controlled trials to support one approach over another. In this review we summarize the current data available for management and care of the failing allograft. Additionally, we discuss a suggested plan for immunosuppression weaning based upon availability of re-transplantation and residual allograft function. We propose a shared-care model in which there is improved coordination between transplant providers and general nephrologists so that immunosuppression management and preparation for renal replacement therapy and/or repeat transplantation can be conducted with the goal of improved outcomes and decreased morbidity in this vulnerable patient group. This article is protected by copyright. All rights reserved.Entities:
Year: 2021 PMID: 34115439 DOI: 10.1111/ajt.16717
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086